References to accompany the February 2017 issue of Kai Tiaki Nursing New Zealand

1. Schaffir, J., Worley, B. & Gurr, T. (2016). Combined hormonal contraception and its effects on mood: a critical review. The European Journal of Contraception and Reproductive health Care. 21(5): 347-355.
2. Skovlund, C. et al. (2016). Association of hormonal contraception with depression. JAMA Psychiatry. 73(11): 1154-1162.
3. Norman, A. & Henry, H. (2015). Hormones. (3^rd ed.). London: Academic Press.
4. Weinbauer, G. et al. (2010). Physiology of testicular function. In Nieschlag, E et al. (eds.). Andrology. Berlin: Springer-Verlag.
5. Davis, S. & Worsley, R. (2013). Androgen treatment of post-menopausal women. Journal of Steroid Biochemistry and Molecular Biology. 142: 107-114.
6. Giatti, S., Melcangi, C. & Pesaresi, M. (2016). The other side of progestins: effects in the brain. Journal of Molecular Endocrinology. 57: R109-R126.
7. Barrett-Connor, E. et al. (2006). Effects of raloxifene on cardiovascular events and breast cancer in post-menopausal women. New England Journal of Medicine. 355(2): 125-137. 
8. Tchaikovski, S. & Rosing, J. (2010). Mechanisms of estrogen-induced venous thromboembolism. Thrombosis Research. 126(1): 5-11.
9. Woods, G. et al. (2016). A review of hormonal contraception and venous thromboembolism in adolescents. Journal of Pediatric and Adolescent Gynecology. 29(5): 402-408.
10. Eisenberger, A. & Westhoff, C. (2014). Hormone replacement therapy and venous thromboembolism. The Journal of Steroid Biochemistry and Molecular Biology. 142: 76-82.
11. Mohammed, K. et al. (2015). Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism. 100: 4012-4020.
12. Scarab, P-Y., et al. (2016). Letter to the editor: Transdermal vs oral estrogen therapy and venous thromboembolism: Upgrade the level of evidence. The Journal of Clinical Endocrinology and Metabolism. 101(2): L30-L31.
13. Brinton, R. et al. (2015). Perimenopause as a neurological transition state. Nature Reviews Endocrinology. 11: 393-405.
14. Soares, C. & Zitek, B. (2008). Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? Journal of Psychiatry and Neuroscience. 33(4): 331-343.
15. Dubey, N. et al. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry. 00:1-13.
16. Gordon, j. et al. (2015). Ovarian hormone fluctuations, neurosteroids and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. American Journal of Psychiatry. 172(3):227-236.
17. Gurney, E. et al. (2014). The Women’s Health Initiative trial and related studies: 10 years later: A clinician’s view. The Journal of Steroid Biochemistry and Molecular Biology. 142: 4-11.
18. Lobo, R. (2014). Forward. The Journal of Steroid Biochemistry and Molecular Biology. 142: 3.
19. NICE: National Institute for Health and Care Excellence. (2015). Menopause. Acchttps://www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261essed January 2017. 
20. Australasian Menopause Society. (2014). Bioidentical hormones ofr menopausal symtoms. Accessed January 2017. https://www.menopause.org.au/images/stories/infosheets/docs/AMS_Bioidentical_Hormones_for_Menopausal_Symptoms.pdf
21. Files, J., Ko, M. & Pruthi, S. (2011). Bioidentical hormone therapy. Mayo Clinic Proceedings.  86(7): 673-680.
22. Guardard, A., et al. (2016). Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews. Accessed January 2017. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010407.pub2/abstract